203 related articles for article (PubMed ID: 20804567)
1. The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Gastaldi S; Comoglio PM; Trusolino L
Breast Cancer Res; 2010; 12(4):208. PubMed ID: 20804567
[TBL] [Abstract][Full Text] [Related]
2. Basal breast cancer: a complex and deadly molecular subtype.
Bertucci F; Finetti P; Birnbaum D
Curr Mol Med; 2012 Jan; 12(1):96-110. PubMed ID: 22082486
[TBL] [Abstract][Full Text] [Related]
3. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.
Toft DJ; Cryns VL
Mol Endocrinol; 2011 Feb; 25(2):199-211. PubMed ID: 20861225
[TBL] [Abstract][Full Text] [Related]
4. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
Gastaldi S; Sassi F; Accornero P; Torti D; Galimi F; Migliardi G; Molyneux G; Perera T; Comoglio PM; Boccaccio C; Smalley MJ; Bertotti A; Trusolino L
Oncogene; 2013 Mar; 32(11):1428-40. PubMed ID: 22562252
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer.
Alam MS; Sultana A; Sun H; Wu J; Guo F; Li Q; Ren H; Hao Z; Zhang Y; Wang G
Front Pharmacol; 2022; 13():942126. PubMed ID: 36204232
[TBL] [Abstract][Full Text] [Related]
6. The Interaction of
Zoungrana LI; Krause-Hauch M; Wang H; Fatmi MK; Bates L; Li Z; Kulkarni P; Ren D; Li J
Cells; 2022 Jun; 11(13):. PubMed ID: 35805130
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy.
Hussain Y; Khan H; Alam W; Aschner M; Abdullah ; Alsharif KF; Saso L
Oxid Med Cell Longev; 2022; 2022():4831833. PubMed ID: 35795855
[TBL] [Abstract][Full Text] [Related]
8. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
Alam MS; Sultana A; Reza MS; Amanullah M; Kabir SR; Mollah MNH
PLoS One; 2022; 17(5):e0268967. PubMed ID: 35617355
[TBL] [Abstract][Full Text] [Related]
9. Statistics and network-based approaches to identify molecular mechanisms that drive the progression of breast cancer.
Alam MS; Rahaman MM; Sultana A; Wang G; Mollah MNH
Comput Biol Med; 2022 Jun; 145():105508. PubMed ID: 35447458
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma.
Zhang S; Wang Y; Cao Y; Wu J; Zhang Z; Ren H; Xu X; Kaznacheyeva E; Li Q; Wang G
Front Pharmacol; 2022; 13():851832. PubMed ID: 35370635
[TBL] [Abstract][Full Text] [Related]
11. Combined Network Pharmacology and Cytology Experiments to Identify Potential Anti-Breast Cancer Targets and Mechanisms of Delphinidin.
Peng J; Wu A; Yu X; Zhong Q; Deng X; Zhu Y
Nutr Cancer; 2022; 74(7):2591-2606. PubMed ID: 34875956
[TBL] [Abstract][Full Text] [Related]
12. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
Omeljaniuk WJ; Krętowski R; Ratajczak-Wrona W; Jabłońska E; Cechowska-Pasko M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768941
[TBL] [Abstract][Full Text] [Related]
13. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
Wang Z; Hu S; Li X; Liu Z; Han D; Wang Y; Wei L; Zhang G; Wang X
BMC Cancer; 2021 Nov; 21(1):1188. PubMed ID: 34743685
[TBL] [Abstract][Full Text] [Related]
14. Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis.
Zeng X; Shi G; He Q; Zhu P
Sci Rep; 2021 Oct; 11(1):20799. PubMed ID: 34675265
[TBL] [Abstract][Full Text] [Related]
15. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses.
Xiao X; Zhang Z; Luo R; Peng R; Sun Y; Wang J; Chen X
Oncol Lett; 2021 May; 21(5):363. PubMed ID: 33747220
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation biomarkers for nasopharyngeal carcinoma.
Han B; Yang X; Zhang P; Zhang Y; Tu Y; He Z; Li Y; Yuan J; Dong Y; Hosseini DK; Zhou T; Sun H
PLoS One; 2020; 15(4):e0230524. PubMed ID: 32271791
[TBL] [Abstract][Full Text] [Related]
18. Screening of Prognostic Factors in Early-Onset Breast Cancer.
Yu Z; He Q; Xu G
Technol Cancer Res Treat; 2020; 19():1533033819893670. PubMed ID: 32028860
[TBL] [Abstract][Full Text] [Related]
19. A Review of Recent Developments and Progress in Computational Drug Repositioning.
Shi W; Chen X; Deng L
Curr Pharm Des; 2020; 26(26):3059-3068. PubMed ID: 31951162
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance.
Hermawan A; Putri H; Utomo RY
Mol Divers; 2020 Nov; 24(4):933-947. PubMed ID: 31659695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
